Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

96.94EUR
11:35am EDT
Change (% chg)

€-0.07 (-0.07%)
Prev Close
€97.01
Open
€96.67
Day's High
€97.36
Day's Low
€96.67
Volume
192,271
Avg. Vol
468,343
52-wk High
€100.35
52-wk Low
€70.68

Latest Key Developments (Source: Significant Developments)

Merck KGaA says fertility unit benefiting from production problems at 2 U.S. rivals
Thursday, 4 Aug 2016 04:48am EDT 

Merck KGaA media call : CEO on fertility business, benefiting from 2 competing products in U.S. held back by production problems . CEO says unclear how long positive effect will last because production of one rival fertility product has resumed . CEO says will file for first avelumab approval in U.S. at end-Q3, in Europe towards year-end . CEO says currently have no active plans to divest any businesses, though constantly reviewing our portfolio . CFO says acquisitions worth more than 500 million eur not on the agenda for next 2 years Further company coverage: [MRCG.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Germany's Merck KGaA, AmoyDx collaborate to bring liquid biopsy RAS biomarker testing to China
Thursday, 28 Jul 2016 02:46am EDT 

Merck KGaA : Merck and Amoy Diagnostics Co Ltd collaborate to bring liquid biopsy RAS biomarker testing to China . Merck and AmoyDx plan to implement ADx-SuperARMS liquid biopsy RAS test in Chinese medical centers in 2017​ .Merck and AmoyDx ‍plan to expand into other markets such as Argentina, India, Mexico, Taiwan, Hong Kong, Brazil, Russia by 2019​.  Full Article

India's Merck Ltd June-qtr profit up about 6 pct
Monday, 25 Jul 2016 06:24am EDT 

Merck Ltd : India's Merck Ltd - June-quarter net profit 179 million rupees; net sales 2.53 billion rupees . Net profit in June-quarter last year was 168.6 million rupees; net sales was 2.41 billion rupees .  Full Article

Merck says EMA accepts cladribine for review marketing authorisation application
Monday, 18 Jul 2016 02:00am EDT 

Merck Kgaa :EMA has accepted for review marketing authorization application (MAA) of investigational product cladribine tablets for treatment of relapsing-remitting multiple sclerosis.  Full Article

BRIEF-Pfizer and Germany's Merck KGaA initiate phase III trial
Thursday, 7 Jul 2016 11:56am EDT 

Pfizer Inc : Merck KGaA and Pfizer initiate phase III trial to evaluate avelumab as first-line treatment for ovarian cancer . New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women .First phase III trial evaluating addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer.  Full Article

Pfizer and Merck initiate phase III trial
Wednesday, 6 Jul 2016 08:00am EDT 

Pfizer Inc : Merck and Pfizer initiate phase III trial to evaluate avelumab as first-line treatment for ovarian cancer . New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women .First phase III trial evaluating addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer.  Full Article

Merck KGaA says plans to apply for authorization for Avelumab in H2
Monday, 20 Jun 2016 05:00am EDT 

Merck Kgaa : Says plan to apply for marketing authorization for avelumab against merkel cell carcinoma in h2 2016 Further company coverage: [MRCG.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1272;)).  Full Article

Merck KGaA partners with Array BioPharma, Pierre Fabre on mCRC phase iii trial
Saturday, 4 Jun 2016 09:23am EDT 

Merck KGaA : Says partners with Array BioPharma and Pierre Fabre to initiate braf-mutant mCRC phase iii trial Further company coverage: [MRCG.DE] ((frankfurt.newsroom@thomsonreuters.com; +496975651270;)).  Full Article

Merck KGaA publishes Chinese Phase III study for Erbitux - Reuters
Monday, 25 Apr 2016 02:11am EDT 

Merck KGaA:Says phase III tailor landmark study demonstrates significant benefits of erbitux in combination with folfox over folfox alone - Reuters.Says marks a major milestone of merck’s oncology strategy including expansion in growth markets.Says will work with relevant authorities to make erbitux available for patients in china as a first - line treatment as soon as possible.  Full Article

Merck KGaA issues FY 2016 outlook, to propose FY 2015 dividend
Tuesday, 8 Mar 2016 01:00am EST 

Merck KGaA:Expects slight organic sales growth in 2016, low double-digit pct increase in adjusted EBITDA.Proposes annual dividend of 1.05 euros per share vs poll avg of 1.09 euros per share.FY 2016 revenue 15,310 million euros - Thomson Reuters I/B/E/S.FY 2016 EBITDA 4,314 million euros - Thomson Reuters I/B/E/S.  Full Article

UPDATE 2-Merck KGaA lifts profit forecast on fertility treatment

* Q2 sales of fertility drug Gonal-f jump FX-adjusted 23 pct (Releads, adds details on fertility treatment market, shares)